WO2011074851A3 - Pharmaceutical preparation - Google Patents

Pharmaceutical preparation Download PDF

Info

Publication number
WO2011074851A3
WO2011074851A3 PCT/KR2010/008925 KR2010008925W WO2011074851A3 WO 2011074851 A3 WO2011074851 A3 WO 2011074851A3 KR 2010008925 W KR2010008925 W KR 2010008925W WO 2011074851 A3 WO2011074851 A3 WO 2011074851A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
active ingredient
inner core
coating layer
pharmaceutical preparation
Prior art date
Application number
PCT/KR2010/008925
Other languages
French (fr)
Korean (ko)
Other versions
WO2011074851A2 (en
Inventor
이범진
풍 트란하렌
Original Assignee
㈜유라팜
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ㈜유라팜 filed Critical ㈜유라팜
Publication of WO2011074851A2 publication Critical patent/WO2011074851A2/en
Publication of WO2011074851A3 publication Critical patent/WO2011074851A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides a pharmaceutical preparation comprising: an inner core including an acidulant and bambuterol or a pharmaceutically acceptable salt thereof as an active ingredient; and a coating layer for coating the surface of the inner core, wherein the coating layer includes both a pH-dependent polymer and a pH-independent polymer. When the preparation of the present invention is orally administered, the preparation releases the active ingredient thereof after an elapse of a predetermined delay time after the preparation has been passed from the stomach to the intestine of a patient, thus providing medicinal effects during the time when asthmatic symptoms become severe.
PCT/KR2010/008925 2009-12-14 2010-12-14 Pharmaceutical preparation WO2011074851A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090123838A KR101152977B1 (en) 2009-12-14 2009-12-14 Pharmaceutical Formulation Pharmaceutical Formulation
KR10-2009-0123838 2009-12-14

Publications (2)

Publication Number Publication Date
WO2011074851A2 WO2011074851A2 (en) 2011-06-23
WO2011074851A3 true WO2011074851A3 (en) 2011-11-03

Family

ID=44167850

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/008925 WO2011074851A2 (en) 2009-12-14 2010-12-14 Pharmaceutical preparation

Country Status (2)

Country Link
KR (1) KR101152977B1 (en)
WO (1) WO2011074851A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103288670B (en) * 2013-05-16 2014-11-05 南京医科大学第一附属医院 Polyhydroxy benzophenone derivative and application thereof
CN107668351A (en) * 2017-10-20 2018-02-09 浙江耀飞生物科技有限公司 A kind of enteric solubility compound fodder acidulant

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
WO2003057278A2 (en) * 2002-01-04 2003-07-17 Ivax Research, Inc. Drug delivery system for sustained delivery of glipizide
US6635680B2 (en) * 1999-09-02 2003-10-21 Nostrum Pharmaceuticals, Inc. Controlled release pellet formulation
KR20050112599A (en) * 2004-05-27 2005-12-01 한국화학연구원 Controlled released type drug delivery system
KR20050114921A (en) * 2004-06-02 2005-12-07 씨제이 주식회사 Controlled release pharmaceutical compositions
KR100762846B1 (en) * 2003-09-29 2007-10-04 씨제이 주식회사 Sustained-release formulations
KR20080026754A (en) * 2006-09-21 2008-03-26 주식회사 삼양사 Release controlled particle comprising a biologically active substance, and preparing method thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US6635680B2 (en) * 1999-09-02 2003-10-21 Nostrum Pharmaceuticals, Inc. Controlled release pellet formulation
WO2003057278A2 (en) * 2002-01-04 2003-07-17 Ivax Research, Inc. Drug delivery system for sustained delivery of glipizide
KR100762846B1 (en) * 2003-09-29 2007-10-04 씨제이 주식회사 Sustained-release formulations
KR20050112599A (en) * 2004-05-27 2005-12-01 한국화학연구원 Controlled released type drug delivery system
KR20050114921A (en) * 2004-06-02 2005-12-07 씨제이 주식회사 Controlled release pharmaceutical compositions
KR20080026754A (en) * 2006-09-21 2008-03-26 주식회사 삼양사 Release controlled particle comprising a biologically active substance, and preparing method thereof

Also Published As

Publication number Publication date
KR20110067302A (en) 2011-06-22
KR101152977B1 (en) 2012-06-11
WO2011074851A2 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
WO2011139044A2 (en) Controlled-release pharmaceutical composition including tamsulosin or the pharmaceutically acceptable salts thereof, and oral preparation including same
JP2013540807A5 (en)
WO2010062688A3 (en) Dosage form for insertion into the mouth
WO2009085990A3 (en) Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
WO2012020097A3 (en) Use of binders for manufacturing storage stable formulations
WO2013012199A8 (en) Capsule formulation comprising montelukast and levocetirizine
HRP20201316T1 (en) Novel modulators of sphingosine phosphate receptors
WO2015020943A3 (en) Digestive enzyme composition suitable for enteral administration
RU2013136350A (en) PHARMACEUTICAL COMPOSITION CONTAINING OPIOID AGONIST AND SECKED ANTAGONIST
JP2013508289A5 (en)
WO2011111027A3 (en) Oral dispersible delayed release tablet formulation
NZ594311A (en) Pharmaceutical composition comprising tamsulosin and solifenacin for oral administration
WO2012010669A3 (en) Medicinal drug for oral administration comprising a mixture of silodosin and a basic copolymer
WO2012047182A3 (en) Single dose dry powder inhalation device
WO2010090494A3 (en) Medical use of 5-benzylaminosalicylic acid derivatives or salts thereof
WO2012053785A3 (en) Sustained-release pellets containing tacrolimus as an active ingredient
WO2011037976A3 (en) Pramipexole pharmaceutical formulations
WO2013026558A3 (en) Combined therapeutic agent
TN2011000307A1 (en) Galenic formulation of organic compounds
WO2007145863A3 (en) Sustained release formulation of naltrexone
JP2013536837A5 (en)
WO2011093818A3 (en) Pharmaceutical compositions comprising salmeterol and fluticasone
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone
WO2011074851A3 (en) Pharmaceutical preparation
WO2011083402A3 (en) Immediate release compositions of acid labile drugs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10837847

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10837847

Country of ref document: EP

Kind code of ref document: A2